<DOC>
	<DOC>NCT03092882</DOC>
	<brief_summary>The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with uncontrolled Type 2 diabetes.</brief_summary>
	<brief_title>Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Imidacloprid</mesh_term>
	<criteria>Humana Medicare Advantage member Type 2 diabetes diagnosis HbA1c levels â‰¥ 8.0% verified by lab test Has any of the following conditions: cancer, chronic heart failure, chronic obstructive pulmonary disease, respiratory failure, chronic kidney disease, end stage renal disease, peripheral vascular disease Not fluent in English Humana membership is part of a Full or Global risk arrangement Enrolled in Humana at Home Care Management</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>